Adaptimmune Therapeutics News and Activities

Adaptimmune Therapeutics is a company listed under the stock ticker ADAP (US).

View the org chart displaying its 11 main executives

Most searched biographies at Adaptimmune Therapeutics

• Chris Hill, Chief Executive Officer and Chief Financial Officer
• Lawrence Alleva, Chairman of the Board
• Garry Menzel, Non-Executive Director

Popular executive movements at Adaptimmune Therapeutics

• Adrian Rawcliffe, Chief Executive Officer and Director, has left the company  (posted on November 18 2025).
• David Mott, Chairman of the Board, has left the company  (posted on November 18 2025).
• Kristen Hege, Non-Executive Director, has left the company  (posted on November 18 2025).

Click here to view some more movements at Adaptimmune Therapeutics

Create your alert
to follow the executive moves at Adaptimmune Therapeutics.

Adaptimmune Therapeutics has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Patrick Enright - Director at CuraSen Therapeutics

Learn more about the Biotechnology industry

Press releases by Adaptimmune Therapeutics

• Adaptimmune Reports Q3 2024 Financial and Business Updates
• Virtual KOL event to review lete-cel final data and discuss sarcoma franchise, Monday, November 18, 2024; 2:30 PM EST
• Connective Tissue Oncology Society (CTOS) 2024 Annual Meeting
• Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial
• Adaptimmune to Participate in Scientific and Medical Conferences this November and December
• Q3 Financial and Business Update
• Adaptimmune to Report Q3 2024 Financial and Business Updates on Wednesday, November 13, 2024
• Q3 Financial and Business Update
• H.C. Wainwright 26th Annual Global Investment Conference
• H.C. Wainwright 26th Annual Global Investment Conference
• View more press releases Close

Social media about Adaptimmune Therapeutics

• Adaptimmune Therapeutics on Wikipedia, Google News & Yahoo Finance
• Adaptimmune Therapeutics on LinkedIn, X (Twitter) & YouTube